Kathryn L Chapman

Summary

Country: UK

Publications

  1. ncbi The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primates
    Kathryn L Chapman
    National Centre for Replacement, Refinement and Reduction of Animals in Research, Gibbs Building, 215 Euston Rd, London NW1 2BE, UK
    Regul Toxicol Pharmacol 62:347-54. 2012
  2. ncbi Preclinical safety testing of monoclonal antibodies: the significance of species relevance
    Kathryn Chapman
    National Centre for the Replacement, Refinement and Reduction of Animals in Research, 20 Park Crescent, London W1B 1AL, UK
    Nat Rev Drug Discov 6:120-6. 2007
  3. ncbi Preclinical development of monoclonal antibodies: considerations for the use of non-human primates
    Kathryn Chapman
    National Centre for Replacement, Refinement and Reduction of Animals in Research, London, UK
    MAbs 1:505-16. 2009
  4. ncbi The future of non-human primate use in mAb development
    Kathryn L Chapman
    National Centre for the Replacement, Refinement and Reduction of Animals in Research, 20 Park Crescent, London W1B1AL, UK
    Drug Discov Today 15:235-42. 2010
  5. ncbi The value of acute toxicity studies to support the clinical management of overdose and poisoning: a cross-discipline consensus
    Kathryn Chapman
    National Centre for the Replacement, Refinement and Reduction of Animals in Research, London, UK
    Regul Toxicol Pharmacol 58:354-9. 2010
  6. ncbi Working in partnership to advance the 3Rs in toxicity testing
    Anthony M Holmes
    National Centre for the Replacement, Refinement and Reduction of Animals in Research, 20 Park Crescent, London W1B1AL, UK
    Toxicology 267:14-9. 2010
  7. ncbi A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development
    Sally Robinson
    AstraZeneca, Alderley Park, UK
    Regul Toxicol Pharmacol 50:345-52. 2008

Collaborators

Detail Information

Publications7

  1. ncbi The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primates
    Kathryn L Chapman
    National Centre for Replacement, Refinement and Reduction of Animals in Research, Gibbs Building, 215 Euston Rd, London NW1 2BE, UK
    Regul Toxicol Pharmacol 62:347-54. 2012
    ..They include guidance on the main group size, the inclusion of recovery groups and the number of dose groups used in short and long term chronic toxicology studies...
  2. ncbi Preclinical safety testing of monoclonal antibodies: the significance of species relevance
    Kathryn Chapman
    National Centre for the Replacement, Refinement and Reduction of Animals in Research, 20 Park Crescent, London W1B 1AL, UK
    Nat Rev Drug Discov 6:120-6. 2007
    ....
  3. ncbi Preclinical development of monoclonal antibodies: considerations for the use of non-human primates
    Kathryn Chapman
    National Centre for Replacement, Refinement and Reduction of Animals in Research, London, UK
    MAbs 1:505-16. 2009
    ..The addendum of ICHS6 provides a timely opportunity for the scientific and regulatory community to embrace strategies which minimize primate use and increase efficiency of mAb development...
  4. ncbi The future of non-human primate use in mAb development
    Kathryn L Chapman
    National Centre for the Replacement, Refinement and Reduction of Animals in Research, 20 Park Crescent, London W1B1AL, UK
    Drug Discov Today 15:235-42. 2010
    ..In this article, the authors review current and future NHP use in mAb development based on surveys, experience and expert opinion and propose a framework that will minimize future NHP use and continue to support science and innovation...
  5. ncbi The value of acute toxicity studies to support the clinical management of overdose and poisoning: a cross-discipline consensus
    Kathryn Chapman
    National Centre for the Replacement, Refinement and Reduction of Animals in Research, London, UK
    Regul Toxicol Pharmacol 58:354-9. 2010
    ....
  6. ncbi Working in partnership to advance the 3Rs in toxicity testing
    Anthony M Holmes
    National Centre for the Replacement, Refinement and Reduction of Animals in Research, 20 Park Crescent, London W1B1AL, UK
    Toxicology 267:14-9. 2010
    ..This review highlights the mechanisms by which the NC3Rs is working with the pharmaceutical and chemical industries and regulatory authorities to achieve these goals...
  7. ncbi A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development
    Sally Robinson
    AstraZeneca, Alderley Park, UK
    Regul Toxicol Pharmacol 50:345-52. 2008
    ..The conclusions have been discussed and agreed with representatives of regulatory bodies from the US, Japan and Europe...